Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Immunoadsorption and subsequent immunoglobulin G replacement (IA/IG) in patients with dilated cardiomyopathy: a systematic review and meta-analysis
Clinical Scorecard: Evaluation of Immunoadsorption and Immunoglobulin G Replacement Therapy in Dilated Cardiomyopathy: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Dilated Cardiomyopathy (DCM)
Key Mechanisms
Immunoadsorption combined with immunoglobulin G replacement therapy (IA/IG) targets autoantibody-mediated myocardial injury.
Target Population
Patients with dilated cardiomyopathy.
Care Setting
Clinical trials and systematic reviews.
Key Highlights
IA/IG therapy significantly improved left ventricular ejection fraction (LVEF) by 7.71%.
Reduction in left ventricular end-diastolic dimension (LVEDD) by 3.22 mm was observed.
Improvements in NYHA functional class and peak VOâ‚‚ were noted.
The study included 18 studies with 809 participants.
Sensitivity analysis indicated stability of results.
Guideline-Based Recommendations
Diagnosis
Diagnosis of DCM should consider clinical symptoms, imaging, and biomarkers.
Management
IA/IG therapy may be considered for improving cardiac function in DCM patients.
Monitoring & Follow-up
Monitor left ventricular ejection fraction and functional class during treatment.
Risks
Limited number of RCTs suggests caution in interpreting results.
Patient & Prescribing Data
Patients diagnosed with dilated cardiomyopathy, particularly those with refractory symptoms.
IA/IG therapy may provide a complementary treatment option for patients with unsatisfactory pharmacologic outcomes.
Clinical Best Practices
Conduct further high-quality, large-scale trials to confirm IA/IG therapy benefits.
Utilize systematic reviews to guide treatment protocols.
A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.
